Triaziquone

Triaziquone

SCHEMBL20359693

NC(N)=O.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1.OB(O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.39
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
STAT3 P40763 1/20 0.37
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
TDP2 O95551 3/20 0.33
HKDC1 Q2TB90 3/20 0.33
APAF1 O14727 2/20 0.33
NSD2 O96028 2/20 0.33
MEN1 O00255 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
GALK1 P51570 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL145372 0.93 DNMT1 (0.43) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL8387982 0.89 DNMT1 (0.34) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL8848720 0.86 DNMT1 (0.39) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL21805762 0.86 MAPT (0.40) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL4608905 0.85 DNMT1 (0.43) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL8303 0.85 DNMT1 (0.48) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL975384 0.85 DNMT1 (0.38) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL1241564 0.84 TP53 (0.36) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL10906735 0.84 HTT (0.43) DNMT1HTTSMN1; SMN2TP53MAPT
Triaziquone SCHEMBL8926769 0.84 DNMT1 (0.42) DNMT1HTTSMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2023-01-26 US disclosed
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP DNMT1 239/4885HTT 3101/4885SMN1; SMN2 2890/4885
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP DNMT1 239/4885HTT 3101/4885SMN1; SMN2 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.